Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › fallopian tube carcinoma

Fallopian tube carcinoma

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for fallopian tube carcinoma

9 trials tracked for fallopian tube carcinoma.

9Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 9
  1. Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  2. Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed
  3. Phase 2 A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer Completed
  4. Phase 2 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  5. Phase 2 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Completed
  6. Phase 2 EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
Show 3 more trials
  1. Phase 2 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed
  2. Phase 2 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma Completed
  3. Phase 2 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
Oncology RCT
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Apr 23, 2026